+ TREVENTIS Corporation is a biotechnology company focused on diseases associated with protein misfolding. Treventis uses a computational platform to rationally design small molecule therapeutics for protein misfolding diseases. Our lead program in Alzheimer’s Disease therapeutics is now the subject of a robust collaboration with Servier Laboratories. We have a team of chemists and biologists with leading expertise in this area and are expanding on our proprietary pipeline in Parkinson’s, ALS, an undisclosed oncology target and in rare diseases. We also have a diagnostics division for the early identification of Alzheimer’s disease.
Protein Misfolding (taken from Treventis)
Protein production is a carefully orchestrated process that guides each new string of amino acids to fold into a specific, ordered shape. A very small proportion of proteins made in the body do not form an ordered shape, but are said to be “intrinsically disordered”.
Usually, these poorly folded proteins are tightly controlled and degraded by the cell’s protein recycling system.
But in protein folding disorders, intrinsically disordered proteins are produced faster than they can be degraded.
If they stay as monomers they are relatively benign, but a small proportion of these proteins will bind together to form a template, onto which other proteins bind to form oligomers.
These oligomers can be highly toxic and pathogenic.
And so after capturing clean modern head shots of the entire team in a tiny boardroom, I played in the lab for an hour or so, working with labcoats and microscopes. It's a privilege to work with scientists and thinkers on the cutting edge of new research. They devote their lives to keeping us healthier and ending some of the most debilitating diseases.
Check the newly revamped Treventis website here - www.treventis.com